-
1.发明申请公开(公告)号：US20110250134A1
公开(公告)日：2011-10-13
申请号：US13086346
申请日：2011-04-13
申请人： Pedro Cabrales , Adam Friedman , Joel M. Friedman
发明人： Pedro Cabrales , Adam Friedman , Joel M. Friedman
IPC分类号： A61K51/06 , A61K38/48 , A61K38/49 , A61K39/395 , A61K38/14 , A61K9/14 , A61P9/00 , A61P9/10 , A61P7/02 , A61P25/00 , A61P25/18 , A61P35/00 , A61P29/00 , A61P23/02 , A61P31/00 , A61P37/06 , A61K31/722 , B82Y5/00
CPC分类号： A61K49/0002 , A61K9/0024 , A61K9/10 , A61K9/19 , A61K9/5161 , A61K31/722 , A61K38/00 , A61K47/02 , A61K51/1244 , B82Y5/00
摘要： The invention provides methods for delivering a NO molecule or precursor thereof to a vascular compartment of a subject comprising: administering to the subject, a NO particle formulation, via an intravascular, intraperitoneal, or intramuscular administration, in an amount sufficient to induce vascular smooth muscle relaxation thereby delivering the NO molecule or precursor thereof to the vascular compartment of the subject, wherein the NO particle formulation comprises NO attached to a nanoparticle or microparticle.
摘要翻译： 本发明提供了将NO分子或其前体递送到受试者的血管隔室的方法，包括：以足以诱导血管平滑肌的量经由血管内，腹膜内或肌肉内施用给受试者的NO颗粒制剂 松弛，从而将NO分子或其前体递送到受试者的血管隔室，其中NO颗粒制剂包含附着于纳米颗粒或微粒的NO。
-
公开(公告)号：US09737478B2
公开(公告)日：2017-08-22
申请号：US12881124
申请日：2010-09-13
IPC分类号： A61K9/00 , A61K9/20 , A61K9/28 , A61K31/137 , A61K31/155 , A61K31/357 , A61K31/4706 , A61K31/4709 , A61K31/49 , A61K31/505 , A61K45/06 , A61K31/365
CPC分类号： A61K9/0019 , A61K9/0004 , A61K9/2004 , A61K9/2806 , A61K31/137 , A61K31/155 , A61K31/357 , A61K31/365 , A61K31/4706 , A61K31/4709 , A61K31/49 , A61K31/505 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： The invention contemplates compositions for the treatment of malaria comprising an anti-malaria drug and an adjuvant which promotes vasodilation and methods of using same.
-
公开(公告)号：US08071546B2
公开(公告)日：2011-12-06
申请号：US11921689
申请日：2006-06-09
CPC分类号： A61K38/38 , A61K9/0019
摘要： The present invention is directed to uses of PEGylated albumins which include methods of treating reduced functional capillary density, reduced blood volume, septic shock and cardiac arrhythmia in a subject, which comprise administering to the subject a therapeutically effective amount of a PEGylated albumin.
摘要翻译： 本发明涉及聚乙二醇化蛋白质的用途，其包括治疗受试者中功能性毛细血管密度降低，血液体积减少，败血性休克和心律失常的方法，其包括向受试者施用治疗有效量的聚乙二醇化白蛋白。
-
公开(公告)号：US20100222260A1
公开(公告)日：2010-09-02
申请号：US11921689
申请日：2006-06-09
CPC分类号： A61K38/38 , A61K9/0019
摘要： The present invention is directed to uses of PEGylated albumins which include methods of treating reduced functional capillary density, reduced blood volume, septic shock and cardiac arrhythmia in a subject, which comprise administering to the subject a therapeutically effective amount of a PEGylated albumin.
摘要翻译： 本发明涉及聚乙二醇化白蛋白的用途，其包括治疗受试者中功能性毛细血管密度降低，血液体积减少，败血性休克和心律失常的方法，其包括向受试者施用治疗有效量的聚乙二醇化白蛋白。
-
公开(公告)号：US20130310325A1
公开(公告)日：2013-11-21
申请号：US13825779
申请日：2011-09-23
IPC分类号： A61K38/57 , A61K31/195 , A61K31/24
CPC分类号： A61K31/195 , A61K9/0053 , A61K9/08 , A61K31/10 , A61K31/145 , A61K31/155 , A61K31/185 , A61K31/19 , A61K31/216 , A61K31/24 , A61K31/661 , A61K31/765 , A61K38/1722 , A61K38/57 , A61K47/02 , A61K47/10
摘要： The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.
摘要翻译： 本发明人意外地发现，通过将液体高剂量蛋白酶抑制剂制剂施用到胰蛋白酶引入胃肠道的上游位置，可以有效地治疗由休克引起的休克和/或潜在的多器官功能衰竭。 最优选地，例如通过鼻胃管直接施用于通过这种施用有效治疗休克的方案，而不需要向空肠和/或回肠提供大量的蛋白酶抑制剂。
-
公开(公告)号：US20110077258A1
公开(公告)日：2011-03-31
申请号：US12881124
申请日：2010-09-13
IPC分类号： A61K31/357 , A61K31/49 , A61K31/4709 , A61K31/4706 , A61K31/137 , A61K31/155 , A61K31/505 , A61K31/365
CPC分类号： A61K9/0019 , A61K9/0004 , A61K9/2004 , A61K9/2806 , A61K31/137 , A61K31/155 , A61K31/357 , A61K31/365 , A61K31/4706 , A61K31/4709 , A61K31/49 , A61K31/505 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： The invention contemplates compositions for the treatment of malaria comprising an anti-malaria drug and an adjuvant which promotes vasodilation and methods of using same.
摘要翻译： 本发明考虑了用于治疗疟疾的组合物，其包含抗疟疾药物和促进血管舒张的佐剂及其使用方法。
-
7.发明申请COMPOSITION AND PROCESS FOR SYNTHESIZING POLYMERIZED HUMAN SERUM ALBUMIN FOR APPLICATIONS IN TRANSFUSION MEDICINE 审中-公开用于合成聚合人血清白蛋白的组合物和方法用于转移医学应用公开(公告)号：US20120046231A1
公开(公告)日：2012-02-23
申请号：US13215473
申请日：2011-08-23
IPC分类号： A61K38/38 , A61P7/00 , C07K14/765
CPC分类号： A61K38/38
摘要： Described herein is a composition and process for synthesizing a human serum albumin (HSA) based plasma replacement composition that includes a polymerized HSA (PolyHSA) that is chemically stabilized by the reduction of Schiff bases. The PolyHSA may have a molecular weight of at least about 100 kDa and may optionally have a cross-linker to HSA molar ratio of at least about 10:1. The PolyHSA composition is useful for restoring a subject's circulatory volume.
摘要翻译： 本文描述的是用于合成基于血浆白蛋白（HSA）的血浆置换组合物的组合物和方法，其包括通过还原希夫碱化学稳定的聚合的HSA（PolyHSA）。 PolyHSA可以具有至少约100kDa的分子量，并且可以任选地具有至少约10:1的HSA摩尔比的交联剂。 PolyHSA组合物可用于恢复受试者的循环体积。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.04 秒)
